Elutia, Inc. (ELUT)
0.8392
+0.02
(+2.34%)
USD |
NASDAQ |
Nov 16, 13:31
Elutia Debt to Equity Ratio : 1.046 for Sept. 30, 2026
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2026 | 1.046 |
| June 30, 2026 | 0.6854 |
| March 31, 2026 | 0.5146 |
| December 31, 2025 | 0.4037 |
| September 30, 2025 | -0.8777 |
| June 30, 2025 | -0.8922 |
| March 31, 2025 | -0.9669 |
| December 31, 2024 | -0.7329 |
| September 30, 2024 | -0.8394 |
| June 30, 2024 | -0.5313 |
| March 31, 2024 | -0.7115 |
| December 31, 2023 | -1.064 |
| September 30, 2023 | -1.418 |
| Date | Value |
|---|---|
| June 30, 2023 | -1.991 |
| March 31, 2023 | -3.576 |
| December 31, 2022 | -7.828 |
| September 30, 2022 | -3.970 |
| June 30, 2022 | -32.17 |
| March 31, 2022 | 6.881 |
| December 31, 2021 | 3.327 |
| September 30, 2021 | 5.608 |
| June 30, 2021 | 3.049 |
| March 31, 2021 | 3.013 |
| December 31, 2020 | 2.511 |
| September 30, 2020 | -1.447 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| Agenus, Inc. | -2.633 |
| Amgen, Inc. | 3.763 |
| Anika Therapeutics, Inc. | 0.1901 |
| BioCryst Pharmaceuticals, Inc. | -2.084 |
| Imunon, Inc. | 2.646 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 48.19M |
| Total Liabilities (Quarterly) | 32.87M |
| Shareholders Equity (Quarterly) | 15.32M |
| Current Ratio | 2.630 |
| Net Debt Paydown Yield | 12.15% |